Codexis Achieves Development Milestone in Research Agreement with Schering-Plough
Complete the form below to unlock access to ALL audio articles.
Codexis, Inc. has announced that it has achieved an important development milestone under a research agreement with Schering-Plough Corporation.
The objective of the collaboration with Schering-Plough is to generate a biocatalytic process to produce a key intermediate for an undisclosed human therapeutics compound.
This program is based on Codexis' proprietary MolecularBreeding™ pharmaceutical process re-engineering platform.
"The agreement with Schering-Plough was announced in March, and Codexis has quickly met the initial development milestone," said Alan Shaw, Ph.D., Codexis President and Chief Executive Officer.
"We are very pleased with this substantial progress in our collaboration and look forward to continuing to demonstrate the value of our technology to this important partner."
"An increasing number of worldwide pharmaceutical partners are recognizing the Codexis competitive advantage in developing rapid, efficient clinical-scale manufacturing production processes."
